Aim. To investigate the effects of simvastatin therapy on antioxidant enzyme activity and the correction of disturbed antioxidant status in patients with coronary heart disease (CHD) – post-infarction cardiosclerosis (PICS) – in combination with dyslipidemia (DLP). Material and methods. The study included 132 CHD patients with PICS and 20 healthy controls. All participants underwent the measurement of plasma levels of lipids, lipid peroxidation (LP) products – diene conjugates (DC) and 2-thiobarbituric acid reagents (TBAR), antioxidant enzymes – glutathione peroxidase (GP) and superoxide dismutase (SOD) in red blood cells, plasma activity of the antioxidant ceruloplasmin/transferrin system (AOS CP/TF) (electron paramagnetic resonance method), and 24-hour Holter monitoring of electrocardiogram (ECG). Results. The three-month simvastatin therapy (20 mg/day), as a component of the complex cardiac treatment, demonstrated its antioxidant effects and antiperoxidation activity in 60% of CHD patients. The subsequent therapy with 2-ethyl-6-methyl-3-hydroxypyridine sulphate (ES; 375 mg/day) and ubidecarenone (30 mg/ day) normalised the parameters of LP-antioxidant defence (AOD) and the levels of hepatic transaminases. Plasma AOS CP/TF activity inversely correlated with the duration of myocardial ischemia in CHD patients (r=-0,34; p=0,004). Conclusion. To optimise the treatment of atherogenic DLP in simvastatin-treated CHD patients, ubidecarenone and ES could be used to improve the LP-AOD parameters.

The aim of the work was to study the role of atorvastatin in the correction of oxidative stress manifestations in patients with coronary heart disease and dyslipidemnia (DLP). It included 122 patients with stable forms of CHD and 20 practically healthy subjects. Plasma lipids and products of lipid peroxidation (dienic conjugates and compounds reacting with 2-thiobarbituric acid), eryhrocyte antioxidative enzymes glutathione peroxidase and superoxide dismutase were determined by standard methods; activity of the ceruloplasmin/transferrin antioxidant system) was measured by electron paramagnetic resonance. The patients underwent 24 hr ECG Holter monitoring. Atorvastatin at a dose of 20 mg/d given during 6 months exerted antioxidative and antiperoxidative effects in 90% of the patients. It normalized parameters of lipid peroxidation and antioxidant protection thereby improving the clinical course of CHD.

Total cholesterol as well as cholesterol of low and high density lipoproteins, lipid peroxidation products (LPP), such as dienic conjugates and compounds reacting with thiobarbituric acid, were measured in a single blood sample from each of the 295 patients with CHD and 20 apparently healthy subjects. FC II and III angina was diagnosed in 142 and 151 CHD patients respectively. Certain samples were used to additionally detect homocysteine, activity of anti-oxidative enzymes (superoxide dismutase and glutathione peroxidase) in erythrocytes and ceruloplasmin/transferrin anti-oxidative system in plasma. Patients with FC III angina had significantly higher LPP levels but lower activity of tissue and plasma anti-oxidative systems than patients with FC II angina or healthy subjects. Patients with stable forms of CHD showed correlation between lipid composition, LPP contents, homocysteine level, and activity of anti-oxidative enzymes.

Treatment with simvastatin (vasilip) at a daily dose of 20 mg combined with conventional cardiac therapy was given for 3 months to 132 patients with coronary heart disease and postinfarction cardiosclerosis with dyslipidemia. Activity of tissue and plasma antioxidative enzymes increased in 60% of the patients and decreased in 40%. Treatment with antioxidants 2-ethyl-6-methyl-3-oxypiridine succinate (mexidol) and ubichinon (cudesan QIO) improved antioxidative status of the patients and clinical picture of cardiac pathology.

Right ventricular myocardial infarction (RVMI) occurs rather rarely, under the mask of various diseases and is not easy to detect. Hypo-vate prognosis. Intravital diagnosis of RVMI was successful in 4 patients. Location of the lesion and its extent were determined. This article reports two cases of the four. The disease onset manifested with dyspnea, dry cough, attacks of night asphyxia then symptoms of right ventricular failure arose and intensified. The clinical picture, typical ECG signs suggested the RVMI diagnosis. However, its verification, precise localization and estimation of the lesion size were possible only after balanced radioventriculography.